• Annals of surgery · Dec 2023

    Multicenter Study

    Increasing Systemic Immune-Inflammation Index During Treatment in Patients with Advanced Pancreatic Cancer is Associated with Poor Survival - A Retrospective, Multicenter, Cohort Study.

    • van 't LandFreek RFRDepartment of Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Mohammad H Aziz, Nynke Michiels, MieogJ Sven DJSDDepartment of Surgery, Leiden University Medical Center, Leiden, the Netherlands., Bert A Bonsing, LuelmoSaskia A CSACDepartment of Oncology, Leiden University Medical Center, the Netherlands., Marjolein Y V Homs, Bas Groot Koerkamp, Grigorios Papageorgiou, and van EijckCasper H JCHJDepartment of Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands..
    • Department of Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
    • Ann. Surg. 2023 Dec 1; 278 (6): 101810231018-1023.

    Background And ObjectivesA high systemic immune-inflammation index (SIII) at diagnosis of various cancers, including pancreatic cancer, is associated with poor prognosis. The impact of FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan, and oxaliplatin) chemotherapy or stereotactic body radiotherapy on this index is unknown. In addition, the prognostic value of changes in the SIII during treatment is unclear. In this retrospective analysis, we aimed to find answers regarding patients with advanced pancreatic cancer.MethodsPatients with advanced pancreatic cancer treated with FOLFIRINOX chemotherapy alone or with FOLFIRINOX chemotherapy followed by stereotactic body radiotherapy between 2015 and 2021 in 2 tertiary referral centers were included. Baseline characteristics, laboratory values at 3 time points during treatment, and survival outcomes were collected. The patient-specific evolutions of SIII and their association with mortality were assessed with joint models for longitudinal and time-to-event data.ResultsData of 141 patients were analyzed. At a median follow-up time of 23.0 months (95% CI: 14.6-31.3), 97 (69%) patients had died. Median overall survival was 13.2 months (95% CI: 11.0-15.5). During treatment with FOLFIRINOX, the log (SIII) was reduced by -0.588 (95% CI: -0.0978, -0.197; P = 0.003). One unit increase in log (SIII) increased the hazard ratio of dying by 1.604 (95% CI: 1.068-2.409; P = 0.023).ConclusionsIn addition to carbohydrate antigen 19-9, the SIII is a reliable biomarker in patients with advanced pancreatic cancer.Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.

      Pubmed     Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…